While the detection of subclinical atherosclerosis may provide an opportunity for the prevention of cardiovascular disease (CVD), which currently is a leading cause of death in HIV-infected subjects, its diagnosis is a clinical challenge. We aimed to compare the agreement and diagnostic performance of Framingham, SCORE and D:A:D equations for the recognition of subclinical atherosclerosis in HIV patients and to adjust the D:A:D equation using HIV and CVD variables.
Methods and results:
Atherosclerosis was evaluated in 203 HIV-infected individuals by measuring the carotid intima-media thickness (IMT). The CVD risk was calculated using the Framingham, SCORE and D:A:D risk equations. Framingham, SCORE and D:A:D equations showed a low agreement with the IMT (Kappa: 0.219, 0.298, 0.244, respectively; p = 0.743) and a moderate predictive performance, (area under the curve [AUC] = 0.686, 0.665 and 0.716, respectively; p = 0.048), with the D:A:D equation being the most accurate. Atherosclerosis was demonstrated in a significant proportion of subjects with low predicted CVD risk by all three algorithms (16.3%, 17.2%, 17.2%, respectively; p = 0.743). In patients with an estimated low CVD risk atherosclerosis was associated with older age (p = 0.012) and low CD4 counts (p = 0.021). A model was developed to adjust the D:A:D equation; a significant increase in accuracy was obtained when CD4 counts and low-grade albuminuria were included (AUC = 0.772; p < 0.001).
Conclusion:
The D:A:D equation overperforms Framingham and SCORE in HIV patients. However, all three equations underestimate the presence of subclinical atherosclerosis in this population. The accuracy of the D:A:D equation improves when CD4 counts and low-grade albuminuria are incorporated into the equation.
PalellaFJJrDelaneyKMMoormanACLovelessMOFuhrerJSattenGA. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med1998; 338: 853–860.
2.
PalellaFJJrBakerRKMoormanACChmielJSWoodKCBrooksJT. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr2006; 43: 27–34.
3.
TriantVALeeHHadiganCGrinspoonSK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab2007; 92: 2506–2512.
4.
SackoffJEHannaDBPfeifferMRTorianLV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med2006; 145: 397–406.
5.
ManfrediR. HIV infection and advanced age emerging epidemiological, clinical, and management issues. Ageing Res Rev2004; 3: 31–54.
6.
GrinspoonSKGrunfeldCKotlerDPCurrierJSLundgrenJDDubeMP. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation2008; 118: 198–210.
7.
WilsonPWD'AgostinoRBLevyDBelangerAMSilbershatzHKannelWB. Prediction of coronary heart disease using risk factor categories. Circulation1998; 97: 1837–1847.
8.
LawMGFriis-MollerNEl SadrWMWeberRReissPD’Arminio MonforteA. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med2006; 7: 218–230.
9.
ParraSCollBAragonesGMarsillachJBeltranRRullA. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med2009; 11: 225–231.
10.
ConroyRMPyoralaKFitzgeraldAPSansSMenottiADe BackerG. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J2003; 24: 987–1003.
11.
Friis-MollerNThiebautRReissPWeberRD’Arminio MonforteADe WitS. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil2010; 17: 491–501.
12.
LorenzMWvon KeglerSSteinmetzHMarkusHSSitzerM. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke2006; 37: 87–92.
13.
LorenzMWMarkusHSBotsMLRosvallMSitzerM. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation2007; 115: 459–467.
14.
TouboulPJLabreucheJVicautEAmarencoP. Carotid intima-media thickness, plaques, and Framingham risk score as independent determinants of stroke risk. Stroke2005; 36: 1741–1745.
15.
HultenEMitchellJScallyJGibbsBVillinesTC. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart2009; 95: 1826–1835.
16.
LorenzMWStephanCHarmjanzAStaszewskiSBuehlerABickelM. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis2008; 196: 720–726.
17.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.
18.
LichtensteinKAWardDJMoormanACDelaneyKMYoungBPalellaFJJr. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS2001; 15: 1389–1398.
19.
GomezFCampsJSimoJMFerreNJovenJ. Agreement study of methods based on the elimination principle for the measurement of LDL- and HDL-cholesterol compared with ultracentrifugation in patients with liver cirrhosis. Clin Chem2000; 46: 1188–1191.
20.
SansSFitzgeraldAPRoyoDConroyRGrahamI. Calibrating the SCORE cardiovascular risk chart for use in Spain. Rev Esp Cardiol2007; 60: 476–485.
TouboulPJHennericiMGMeairsSAdamsHAmarencoPBornsteinN. Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis2007; 23: 75–80.
23.
SecilMAltayCGulcuACeceHGoktayAYDicleO. Automated measurement of intima-media thickness of carotid arteries in ultrasonography by computer software. Diagn Interv Radiol2005; 11: 105–108.
24.
SteinJHKorcarzCEHurstRTLonnEKendallCBMohlerER. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr2008; 21: 93–111.
25.
LohseNHansenABPedersenGKronborgGGerstoftJSorensenHT. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med2007; 146: 87–95.
26.
CooperJAMillerGJHumphriesSE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis2005; 181: 93–100.
27.
De VisserCLBiloHJThomsenTFGroenierKHMeyboom-deJB. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med2003; 253: 553–562.
28.
ThomsenTFMcGeeDDavidsenMJorgensenT. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol2002; 31: 817–822.
29.
HsuePYLoJCFranklinABolgerAFMartinJNDeeksSG. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation2004; 109: 1603–1608.
30.
HsuePYHuntPWSchnellAKalapusSCHohRGanzP. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS2009; 23: 1059–1067.
31.
Friis-MollerNReissPSabinCAWeberRMonforteAEl SadrW. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med2007; 356: 1723–1735.
32.
SabinCAWormSWWeberRReissPEl SadrWDabisF. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi–cohort collaboration. Lancet2008; 371: 1417–1426.
33.
HughesMDWilliamsPL. Challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med2007; 356: 1705–1707.
34.
HolmbergSDMoormanACWilliamsonJMTongTCWardDJWoodKC. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet2002; 360: 1747–1748.
35.
SankatsingRRWitFWVogelMde GrootEBrinkmanKRockstrohJK. Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors. Atherosclerosis2009; 202: 589–595.
36.
CrucianiMZanichelliVSerpelloniGBoscoOMalenaMMazziR. ABACAVIR use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS2011; 25: 1993–2004.
37.
AkosahKOSchaperACogbillCSchoenfeldP. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform?J Am Coll Cardiol2003; 41: 1475–1479.
38.
PencinaMJD'AgostinoRBSrD'AgostinoRBJrVasanRS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med2008; 27: 157–172.
39.
OlivieroUBonadiesGApuzziVFoggiaMBossoGNappaS. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis2008; 204: 586–589.
40.
SandlerNGWandHRoqueALawMNasonMCNixonDE. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis2011; 203: 780–790.
41.
BrenchleyJMPriceDASchackerTWAsherTESilvestriGRaoS. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med2006; 12: 1365–1371.
42.
TaylorAJLeeHJSullenbergerLE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin2006; 22: 2243–2250.
43.
HoJEDeeksSGHechtFMXieYSchnellAMartinJN. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS2010; 24: 1897–9005.
44.
KaplanRCKingsleyLAGangeSJBenningLJacobsonLPLazarJ. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS2008; 22: 1615–1624.
45.
GuptaSKParkerRARobbinsGKDubeMP. The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons: results from a randomized trial. Nephrol Dial Transplant2005; 20: 2237–2242.
